Free question archive
One cited question a day, kept forever. Answer today's on the daily page.
Head & neck
- Head & neck: Postoperative indications for concurrent chemoRT — high-risk features · 04 September 2026
- Head & neck: Postoperative indications for concurrent chemoRT · 24 August 2026
- Head & neck: Oropharynx — de-intensification and trial enrolment · 13 August 2026
- Head & neck: Oropharynx — definitive concurrent chemoRT (HPV-positive) · 02 August 2026
- Head & neck: Oropharynx — HPV/p16 prognostic significance · 22 July 2026
Urology
- Urology: Muscle-invasive bladder neoadjuvant chemotherapy · 03 September 2026
- Urology: Muscle-invasive bladder bladder-preservation chemoRT · 23 August 2026
- Urology: Low-risk prostate active surveillance · 12 August 2026
- Urology: Prostate ADT duration with radical RT · 01 August 2026
- Urology: Prostate radical RT hypofractionation · 21 July 2026
Respiratory
- Lung: Prophylactic cranial irradiation · 02 September 2026
- Lung: Limited-stage SCLC thoracic RT · 22 August 2026
- Lung: Stage III NSCLC - adjuvant durvalumab · 11 August 2026
- Lung: SABR fractionation · 31 July 2026
- Lung: Radical RT/SABR for early NSCLC · 20 July 2026
Breast
- Breast: Axillary management (Z0011) · 01 September 2026
- Breast: Post-mastectomy radiotherapy · 21 August 2026
- Breast: Tumour-bed boost · 10 August 2026
- Breast: FAST-Forward 5-fraction radiotherapy · 30 July 2026
- Breast: Whole-breast hypofractionation · 19 July 2026
Miscellaneous
- Miscellaneous: Oncological emergency: MSCC · 31 August 2026
- Miscellaneous: CUP: favourable subsets · 20 August 2026
- Miscellaneous: Neuroendocrine tumour: PRRT (NETTER-1) · 09 August 2026
- Miscellaneous: Soft-tissue sarcoma: neoadjuvant vs adjuvant RT · 29 July 2026
Skin
- Skin: Adjuvant systemic therapy stage III and BRAF testing · 30 August 2026
- Skin: Management of a positive sentinel lymph node · 19 August 2026
- Skin: Sentinel lymph node biopsy indication · 08 August 2026
- Skin: Excision margins by Breslow thickness · 28 July 2026
Haematology
- Haematology: Involved-site radiotherapy concept · 29 August 2026
- Haematology: Advanced Hodgkin: response-adapted therapy (RATHL) · 18 August 2026
- Haematology: Early-stage Hodgkin: PET-adapted involved-node RT (H10) · 07 August 2026
- Haematology: Early-stage Hodgkin: combined-modality vs chemotherapy alone (RAPID) · 27 July 2026
Upper GI
- Upper GI: MAGIC trial - perioperative chemotherapy principle · 28 August 2026
- Upper GI: Perioperative chemotherapy gastric (FLOT4 vs MAGIC) · 17 August 2026
- Upper GI: Definitive chemoRT for oesophageal SCC · 06 August 2026
- Upper GI: Oesophageal neoadjuvant chemoradiotherapy (CROSS) · 26 July 2026
Gynaecology
- Gynaecology: Endometrial — adjuvant management by risk group · 27 August 2026
- Gynaecology: Cervix — concurrent chemoradiotherapy evidence · 16 August 2026
- Gynaecology: Cervix — FIGO 2018 staging · 05 August 2026
- Gynaecology: Locally advanced cervix — definitive chemoradiotherapy · 25 July 2026
Central nervous system
- CNS: Low-grade glioma risk stratification · 26 August 2026
- CNS: Elderly glioblastoma · 15 August 2026
- CNS: MGMT and IDH significance · 04 August 2026
- CNS: Glioblastoma standard of care · 24 July 2026
Lower GI
- Lower GI: Total neoadjuvant therapy (FOLFIRINOX) · 25 August 2026
- Lower GI: Preoperative versus postoperative chemoradiotherapy · 14 August 2026
- Lower GI: MRI risk stratification for neoadjuvant therapy · 03 August 2026
- Lower GI: Indications for neoadjuvant radiotherapy by stage · 23 July 2026
Weekly FRCR 2A revision email
The week's free questions and one teaching point, in one email. Launching soon — unsubscribe any time. By subscribing you consent to marketing email from FRCR Vault (details in our privacy policy).